EBMT-EHA CAR-T 2019 | CAR T-cell therapy: factors to consider
Mohamad Mohty
• 18 Feb 2019
Mohamad Mohty, MD, PhD Saint-Antoine Hospital, Paris, France, explains the complexity of CAR-T therapy in terms of it’s clinical management and logistics. Speaking at the 1st European CAR T-Cell Meeting, held in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and European Hematology Association (EHA), Professor Mohty goes on to describe how the implementation of a CAR T-cell program and the management of the therapy post-infusion is extremely complex and is what needs to be worked on collaboratively to harmonise and standardise.
